Adicet Bio, Inc. Common Stock (ACET)
PHARMACEUTICAL PREPARATIONS
Adicet Bio, Inc. Common Stock (ACET) is listed on Nasdaq, where it has traded since September 16, 2020.
- Listed On
- Nasdaq
- Listed Since
- September 16, 2020
- Employees
- 102
- Market Cap
- $53M
About Adicet Bio, Inc. Common Stock
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Frequently asked questions
What is ACET?
Adicet Bio, Inc. Common Stock (ACET) is listed on Nasdaq, where it has traded since September 16, 2020.
Every reported institutional holder, plus insider and congressional trades in ACET, on SentiSense.